Transcriptome data (E-TABM-899) was composed of 40 NFPA samples, which were characterized in terms of clinical and pathological features including age, sex, hormonal secretion (LH, FSH), immunohistochemical staining (FSH-β and LH-β and/or α-subunit), tumor volume (0.5–77 cm3), tumor grade (I-IV), follow-up time (3–10.5 years), and outcome (recurrence, stably remnant, and remnant). This evidence concerns the gene BRD2 and non-functioning pituitary adenoma.